Viral Trimeric Antigens Stabilized by Disulfide Bond Belts

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current vaccines for enveloped viruses, such as influenza and HIV, face challenges in stabilizing viral trimeric antigens, which affects their resistance to environmental stress and immune response efficacy.

Innovation Solution

Introduction of a tandem disulfide bond belt formed by two-cysteine mini-domains in the viral surface antigenic proteins, specifically in the transmembrane domain, to stabilize the trimeric structure and enhance immune responses.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Stability of the object's composition

If conventional vaccines for enveloped viruses are used, then the viral surface antigens can be presented to the immune system, but the trimeric structure is unstable and susceptible to environmental stress

Engineering Contradiction:
Improvetrimeric structure stabilityVSAvoidresistance to environmental stress
Core Design Contradiction:
Stability of the object's compositionVSReliability

Solution Approach 1:

The patent introduces a hybrid structure combining viral transmembrane domains with engineered two-cysteine mini-domains. This composite approach creates a stabilized trimeric complex where the cysteine bridges form additional covalent connections between monomers, reinforcing the trimeric structure without altering the antigenic surface properties. The mini-domains act as molecular staples that lock the trimeric configuration against environmental stress.

Inventive Principle:
Principle #40Composite materials

2Reliability

If the viral surface antigens are stabilized using conventional methods, then structural integrity is improved, but the immune response efficacy remains insufficient

Engineering Contradiction:
Improveresistance to pH and temperature treatmentsVSAvoidimmune response efficacy
Core Design Contradiction:
ReliabilityVSProductivity

Solution Approach 1:

The stabilization strategy is applied locally at the transmembrane domain region rather than throughout the entire antigen structure. The two-cysteine mini-domains are specifically positioned in the membrane-anchoring portion of the protein, allowing the immunogenic ectodomain to maintain its native conformation and antigenic determinants while the transmembrane region provides structural reinforcement through disulfide bonding.

Inventive Principle:
Principle #3Local quality

3Strength

If the trimeric structure is stabilized with additional bonds, then resistance to stress increases, but the complexity of the protein structure increases

Engineering Contradiction:
Improveresistance to pH and temperatureVSAvoidprotein structure complexity
Core Design Contradiction:
StrengthVSDevice complexity

Solution Approach 1:

The two-cysteine mini-domains serve as intermediary elements that mediate between the viral transmembrane domain and the trimeric interface. These small, defined peptide sequences (CxxC, CxxxC, or CxxxxC patterns) act as molecular connectors that form disulfide bridges between adjacent monomers, providing structural reinforcement without requiring complex tertiary structures or large domain additions.

Inventive Principle:
Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The stabilization of viral trimeric antigens leads to increased resistance to pH and temperature treatments and elicits stronger cross-reactive immune responses, improving vaccine efficacy against enveloped viruses.

Implementation Method 1

the two cysteines in the two-cysteine mini-domain could form a tandem disulfide bond belt, covalently tighting the homotrimer

Methodology Applied
Scientific EffectDisulfide bond formation: Chemical Bonding

Data Source

PatentUS9060973B2Vaccine for enveloped viruses
Publication Date: 2015.06.23 LIU GEORGE DACAI

AI summary

The present invention provides a recombinant viral surface antigenic protein with enhanced stability. The present invention also provides a vaccine composition against enveloped viruses.